Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
688336
Rang in aandelen
#3772
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a... Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a biopharmaceutical enterprise operating in China. This company is thoroughly engaged in the full lifecycle of antibody-based medicines, from their initial research and development to their production and subsequent market introduction. Its current portfolio includes YISAIPU, a tumor necrosis factor inhibitor utilized for treating rheumatic ailments; Xenopax, a recombinant humanized anti-CD25 monoclonal antibody delivered via injection; and Cipterbin, an anti-HER2 monoclonal antibody. Furthermore, the organization is actively progressing novel treatments designed for autoimmune disorders, various cancers, and other health issues. Established in 2002, its main offices are situated in Shanghai, China.
Aandeelprijs
$4.87
Marktkapitalisatie
$4.36B
Verandering (1 dag)
-5.47%
Verandering (1 jaar)
-15.62%
Land
CN
Handel Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Categorie
Healthcare
Winst voor Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd van 2006 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2025 | $474.32M | 389.24% |
| 2024 | $96.95M | 120.93% |
| 2023 | $43.88M | 945.41% |
| 2022 | $4.20M | -149.98% |
| 2021 | $-8.40M | -80.57% |
| 2020 | $-43.23M | -231.32% |
| 2019 | $32.92M | -44.95% |
| 2018 | $59.80M | -10.08% |
| 2017 | $66.50M | 49.67% |
| 2016 | $44.43M | 21.77% |
| 2015 | $36.49M | -8.05% |
| 2014 | $39.68M | -30.82% |
| 2013 | $57.36M | 23.82% |
| 2012 | $46.33M | 31.47% |
| 2011 | $35.24M | 34.54% |
| 2010 | $26.19M | 67.48% |
| 2009 | $15.64M | 79.66% |
| 2008 | $8.70M | 266.58% |
| 2007 | $2.37M | -158.83% |
| 2006 | $-4.04M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $3.01B | - |
BE
|
|
| $1.95B | - |
NL
|
